专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

61. 发明申请

US20110144146A1 Aminomethyl Substituted Bicyclic Aromatic Compounds Suitable for Treating Disorders That Respond to Modulation of the Dopamine D3 Receptor 失效
公开(公告)号：US20110144146A1
公开(公告)日：2011-06-16
申请号：US11665287
申请日：2005-10-14
申请人： Karla Drescher , Andreas Haupt , Liliane Unger , Sean C. Turner , Wilfried Braje , Roland Grandel
发明人： Karla Drescher , Andreas Haupt , Liliane Unger , Sean C. Turner , Wilfried Braje , Roland Grandel
IPC分类号： A61K31/437 , C07D209/04 , A61K31/405 , A61K31/16 , C07C331/00 , C07D235/00 , A61K31/415 , C07D471/02 , A61K31/40 , A61P25/00
CPC分类号： C07D471/04 , C07D209/14 , C07D209/62 , C07D235/14
摘要： The present invention relates to an aminomethyl substituted bicyclic aromatic compound of the formula I wherein Ar is a cyclic radical selected from the group consisting of phenyl, a 5- or 6-membered C-bound heteroaromatic radical comprising as ring member 1, 2 or 3 heteroatoms which are, independently of each other, selected from O, S and N, and a phenyl ring fused to a saturated or unsaturated 5- or 6-membered carbocyclic or heterocyclic ring, where the heterocyclic ring comprises as ring members 1, 2 or 3 heteroatoms selected from N, 0 and S and/or 1, 2 or 3 heteroatom-containing groups each independently selected from NR8, where R8 is H, C1-C4-alkyl, fluorinated C1-C4-alkyl, C1-C4-alkylcarbonyl or fluorinated C1-C4-alkylcarbonyl, and where the cyclic radical Ar may carry 1, 2 or 3 substituents Ra, wherein the variable Ra has the meanings given in the claims and in the description; X is a covalent bond or N—R2, CHR2, CHR2CH2, N or C—R2; Y is N—R2a, CHR2a, CHR2aCH2 or CHR2aCH2CH2; is a single bond or a double bond; E is CH2 or NR3; R1 is H, C3-C4-cycloalkyl, C3-C4-cycloalkylmethyl, C3-C4-alkenyl, fluorinated C1-C4-alkyl, fluorinated C3-C4-cycloalkyl, fluorinated C3-C4-cycloalkylmethyl, fluorinated C3-C4-alkenyl, formyl or C1-C3-alkylcarbonyl; R1a is H, C1C4-alkyl, C3-C4-cycloalkyl, C3-C4-alkenyl, fluorinated C1-C4-alkyl, fluorinated C3-C4-cycloalkyl, fluorinated C3-C4-alkenyl, R2 and R2a each independently are H, CH3, CH2F, CHF2 or CF3 or R1a and R2 or R1a and R2a together are (CH2)n with n being 1, 2 or 3; R3 is H or C1C4-alkyl; R4 and R5 independently of each other are H, C1-C4-alkyl, fluorinated C1-C4-alkyl or C1-C4-alkoxy or may form, together with N, a 4-, 5- or 6-membered saturated or unsaturated ring; R6 and R7 independently of each other are H or halogen; and the physiologically tolerated acid addition salts thereof.

62. 发明授权

US07851463B2 Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor 有权
标题翻译：适用于治疗对多巴胺D3受体调节作出反应的疾病的杂环化合物
公开(公告)号：US07851463B2
公开(公告)日：2010-12-14
申请号：US11665399
申请日：2005-10-14
申请人： Karla Drescher , Andreas Haupt , Liliane Unger , Sean C. Turner , Wilfried Braje , Roland Grandel , Christophe Henry , Gisela Backfisch , Armin Beyerbach , Wilfried Lubisch
发明人： Karla Drescher , Andreas Haupt , Liliane Unger , Sean C. Turner , Wilfried Braje , Roland Grandel , Christophe Henry , Gisela Backfisch , Armin Beyerbach , Wilfried Lubisch
IPC分类号： A61K31/397 , A61K31/506 , A61K31/4439 , A61K31/40 , C07D239/42 , C07D401/04 , C07D207/04
CPC分类号： C07D413/14 , C07D205/04 , C07D207/09 , C07D211/28 , C07D401/04 , C07D401/12 , C07D403/04 , C07D405/12 , C07D409/12 , C07D413/10 , C07D413/12
摘要： The invention relates to compounds of the formula (I). The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.
摘要翻译：本发明涉及式（I）化合物。本发明还涉及式I化合物或其药学上可接受的盐在制备用于治疗易受多巴胺D3受体配体治疗的医学疾病的药物组合物中的用途。本发明还涉及式I化合物或其药学上可接受的盐在制备用于治疗易受多巴胺D3受体配体治疗的医学疾病的药物组合物中的用途。

63. 发明申请

US20100292220A1 BENZENESULFONANILIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR 有权
标题翻译：适用于治疗依托莫司汀5-HT6受体调节的病症的苯并呋喃半导体化合物
公开(公告)号：US20100292220A1
公开(公告)日：2010-11-18
申请号：US12769878
申请日：2010-04-29
申请人： Andreas Haupt , Frauke Pohlki , Karla Drescher , Karsten Wicke , Liliane Unger , Ana-Lucia Relo , Anton Bespalov , Barbara Vogg , Gisela Backfisch , Juergen Delzer , Min Zhang
发明人： Andreas Haupt , Frauke Pohlki , Karla Drescher , Karsten Wicke , Liliane Unger , Ana-Lucia Relo , Anton Bespalov , Barbara Vogg , Gisela Backfisch , Juergen Delzer , Min Zhang
IPC分类号： A61K31/551 , C07D243/08 , A61P25/28 , A61P25/18 , A61P25/30 , A61P3/04
CPC分类号： C07D243/08 , C07D405/12
摘要： The present invention relates to novel benzenesulfonanilide compounds of the formulae I and I′ and physiologically tolerated acid addition salts and the N-oxides thereof. The compounds possess valuable therapeutic properties and are particularly suitable, for treating diseases that respond to modulation of the serotonin 5-HT6 receptor. wherein R1 is hydrogen or methyl; R2 is hydrogen or methyl and is positioned vicinal to the radical R1; R3 hydrogen, C1-C3 alkyl, halogen, C1-C3 alkoxy, fluorinated C1-C3 alkyl or fluorinated C1-C3 alkoxy; R4 is hydrogen, C1-C4 alkyl, C3-C4 cycloalkyl, C3-C4 cycloalkylmethyl or fluorinated C1-C4 alkyl; R5 is hydrogen, fluorine, chlorine, C1-C4 alkyl, fluorinated C1-C4 alkyl, C1-C4 alkoxy or fluorinated C1-C4 alkoxy; and R6 is hydrogen, fluorine or chlorine.
摘要翻译：本发明涉及式I和I'的新型苯磺酰苯胺化合物和生理上耐受的酸加成盐及其N-氧化物。该化合物具有有价值的治疗特性，特别适用于治疗对血清素5-HT 6受体调节作出反应的疾病。其中R1是氢或甲基; R2是氢或甲基，并且位于基团R1的邻近位置; R3氢，C1-C3烷基，卤素，C1-C3烷氧基，氟化C1-C3烷基或氟化C1-C3烷氧基; R4是氢，C1-C4烷基，C3-C4环烷基，C3-C4环烷基甲基或氟化C1-C4烷基; R5是氢，氟，氯，C1-C4烷基，氟化C1-C4烷基，C1-C4烷氧基或氟化C1-C4烷氧基; R6是氢，氟或氯。

64. 发明申请

US20100210664A1 BENZENESULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR 审中-公开
标题翻译：适用于治疗多巴胺D3受体调节障碍的苯并呋喃半导体化合物
公开(公告)号：US20100210664A1
公开(公告)日：2010-08-19
申请号：US12666627
申请日：2008-10-30
申请人： Sean Colm Turner , Andreas Haupt , Wilfred Braje , Udo Lange , Karla Drescher , Liliane Unger , Ana Lucia Jongen-Relo , Bespalov Anton
发明人： Sean Colm Turner , Andreas Haupt , Wilfred Braje , Udo Lange , Karla Drescher , Liliane Unger , Ana Lucia Jongen-Relo , Bespalov Anton
IPC分类号： A61K31/496 , C07D401/04 , A61P25/00 , A61P25/30 , A61P25/18
CPC分类号： C07D401/04 , C07D213/76
摘要： The invention relates to compounds of the formula R1 is selected from the group consisting of hydrogen, linear C1-C3 alkyl and fluorinated linear C1-C3 alkyl; R2 is hydrogen or methyl; R3 is selected from the group consisting of hydrogen, halogen, C1-C2-alkyl, fluorinated C1-C2-alkyl, C1-C2-alkoxy and fluorinated C1-C2-alkoxy, R4 is C1-C2-alkyl or fluorinated C1-C2-alkyl; n is 0, 1 or 2, and the physiologically tolerated salts of these compounds and the N-oxides thereof. The invention also relates to a pharmaceutical composition that comprises at least one compound of the formula I and/or at least one physiologically tolerated acid addition salt thereof, and further to a method for treating disorders that respond beneficially to dopamine D3 receptor antagonists or dopamine D3 agonists, said method comprising administering an effective amount of at least one compound or physiologically tolerated acid addition salt of the formula I to a subject in need thereof.
摘要翻译：本发明涉及式R1的化合物选自氢，直链C 1 -C 3烷基和氟化线性C 1 -C 3烷基; R2是氢或甲基; R3选自氢，卤素，C1-C2-烷基，氟化C1-C2-烷基，C1-C2-烷氧基和氟化C1-C2-烷氧基，R4是C1-C2-烷基或氟化C1-C2 -烷基; n为0,1或2，以及这些化合物的生理上耐受的盐及其N-氧化物。本发明还涉及包含至少一种式I化合物和/或其至少一种生理上耐受的酸加成盐的药物组合物，还涉及治疗有益于多巴胺D3受体拮抗剂或多巴胺D3的病症的方法所述方法包括向有需要的受试者施用有效量的至少一种式I化合物或生理学上耐受的酸加成盐。

65. 发明授权

US07759397B2 6-amino(aza)indane compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor 失效
标题翻译：适用于治疗对多巴胺D3受体调节作出反应的病症的6-氨基（氮杂）二氢化茚化合物
公开(公告)号：US07759397B2
公开(公告)日：2010-07-20
申请号：US11665420
申请日：2005-10-14
申请人： Karla Drescher , Andreas Haupt , Liliane Unger , Sean C. Turner , Wilfried Braje , Roland Grandel
发明人： Karla Drescher , Andreas Haupt , Liliane Unger , Sean C. Turner , Wilfried Braje , Roland Grandel
IPC分类号： A61K31/135 , C07C211/00
CPC分类号： C07D239/38 , C07C311/21 , C07C2601/02 , C07C2601/04 , C07C2602/08 , C07D221/06 , C07D333/34 , C07D401/12 , C07D409/12
摘要： The present invention relates to 6-amino(aza)indane compound of the formula (I) Wherein Ar is phenyl or an aromatic 5- or 6-membered C-bound heteroaromatic radical, wherein Ar may carry 1 radical Ra and wherein Ar may also carry I or 2 radicals Rb; X is N or CH; E is CR6R7 or NR3; R1 is C1-C4-alkyl, C3-C4-cycloalkyl, C3-C4-cycloalkylmethyl, C3-C4-alkenyl, fluorinated C1-C4-alkyl, fluorinated C3-C4-cycloalkyl, fluorinated C3-C4-cycloalkylmethyl, fluorinated C3-C4-alkenyl, formyl or C1-C3-alkylcarbonyl; R1a is H or R1a and R2 or R1a and R2a together are (CH2)n with n being 1, 2, 3 or 4; R2 and R2a each independently are H, CH3, CH2F, CHF2 or CF3; R3 is H or C,-C4-alkyl; and the physiologically tolerated acid addition salts of these compounds. The invention also relates to pharmaceutical compositions comprising at least one compound of the formula (I) or a pharmaceutically acceptable salt thereof and to a method for treating a medical disorder susceptible to treatment with a dopamine D3 receptor ligand, said method comprising administering an effective amount of at least one compound of the formula (I) or a pharmaceutically acceptable salt thereof.
摘要翻译：本发明涉及式（I）的6-氨基（氮杂）二氢化茚化合物，其中Ar是苯基或芳族5-或6-元C-结合的杂芳族基，其中Ar可以带有1个基团Ra，其中Ar也可以携带I或2个基团Rb; X为N或CH; E为CR6R7或NR3; R 1是C 1 -C 4烷基，C 3 -C 4环烷基，C 3 -C 4环烷基甲基，C 3 -C 4链烯基，氟化C 1 -C 4烷基，氟化C 3 -C 4环烷基，氟化C 3 -C 4环烷基甲基， C4-烯基，甲酰基或C1-C3-烷基羰基; R1a是H或R1a，R2或R1a和R2a同时为（CH2）n，n为1,2,3或4; R2和R2a各自独立地为H，CH3，CH2F，CHF2或CF3; R3是H或C，-C4-烷基; 和这些化合物的生理上耐受的酸加成盐。本发明还涉及包含至少一种式（I）化合物或其药学上可接受的盐的药物组合物和治疗易受多巴胺D3受体配体治疗的医学疾病的方法，所述方法包括施用有效量的至少一种式（I）化合物或其药学上可接受的盐。

66. 发明申请

US20090264437A1 4-Piperazinyl-Pyrimidine Compounds Suitable for Treating Disorders that Respond to Modulation of the Dopamine D3 Receptor 失效
标题翻译：适用于治疗响应多巴胺D3受体调节的疾病的4-哌嗪基 - 嘧啶化合物
公开(公告)号：US20090264437A1
公开(公告)日：2009-10-22
申请号：US11659063
申请日：2005-08-08
申请人： Andreas Haupt , Liliane Unger , Karla Drescher , Ana Lucia Jongen-Relo , Roland Grandel , Wilfried Braje , Herve Geneste
发明人： Andreas Haupt , Liliane Unger , Karla Drescher , Ana Lucia Jongen-Relo , Roland Grandel , Wilfried Braje , Herve Geneste
IPC分类号： A61K31/506 , A61P25/00 , C07D417/14 , C07D403/14 , C07D401/14 , C07D403/04
CPC分类号： C07D239/42 , C07D239/52 , C07D239/56 , C07D401/12 , C07D403/12 , C07D417/12
摘要： The present invention relates to novel 4-piperazinylpyrimidine compounds. The compounds possess valuable therapeutic properties and are suitable, in particular, for treating diseases that respond to modulation of the dopamine D3 receptor. The 4-piperzinylpyrimidine compounds have the general formula I wherein Ar, X, A, R1 and R1a are as defined in the claims.
摘要翻译：本发明涉及新的4-哌嗪基嘧啶化合物。该化合物具有有价值的治疗特性，特别适用于治疗对多巴胺D3受体调节作出反应的疾病。 4-哌嗪基嘧啶化合物具有通式I，其中Ar，X，A，R 1和R 1a如权利要求中所定义。

67. 发明申请

US20080318996A1 6-Amino(Aza)Indane Compounds Suitable for Treating Disorders that Respond to Modulation of the Dopamine D3 Receptor 失效
标题翻译：适用于治疗多巴胺D3受体调节的疾病的6-氨基（氮杂）吲哚化合物
公开(公告)号：US20080318996A1
公开(公告)日：2008-12-25
申请号：US11665420
申请日：2005-10-14
申请人： Karla Drescher , Andreas Haupt , Liliane Unger , Sean C. Turner , Wilfried Braje , Roland Grandel
发明人： Karla Drescher , Andreas Haupt , Liliane Unger , Sean C. Turner , Wilfried Braje , Roland Grandel
IPC分类号： A61K31/435 , C07C311/15 , A61K31/18 , A61P25/00 , C07D221/06
CPC分类号： C07D239/38 , C07C311/21 , C07C2601/02 , C07C2601/04 , C07C2602/08 , C07D221/06 , C07D333/34 , C07D401/12 , C07D409/12
摘要： The present invention relates to 6-amino(aza)indane compound of the formula (I) Wherein Ar is phenyl or an aromatic 5- or 6-membered C-bound heteroaromatic radical, wherein Ar may carry 1 radical R6 and wherein Ar may also carry I or 2 radicals Rb; X is N or CH; E is CR6R7 or NR3; R1 is C1-C4-alkyl, C3-C4-cycloalkyl, C3-C4-cycloalkylmethyl, C3-C4-alkenyl, fluorinated C1-C4-alkyl, fluorinated C3-C4-cycloalkyl, fluorinated C3-C4-cycloalkylmethyl, fluorinated C3-C4-alkenyl, formyl or C1-C3-alkylcarbonyl; R1a is H or R1a and R2 or R1a and R2a together are (CH2)n with n being 1, 2, 3 or 4; R2 and R2a each independently are H, CH3, CH2F, CHF2 or CF3; R3 is H or C,-C4-alkyl; and the physiologically tolerated acid addition salts of these compounds. The invention also relates to pharmaceutical compositions comprising at least one compound of the formula (I) or a pharmaceutically acceptable salt thereof and to a method for treating a medical disorder susceptible to treatment with a dopamine D3 receptor ligand, said method comprising administering an effective amount of at least one compound of the formula (I) or a pharmaceutically acceptable salt thereof.
摘要翻译：本发明涉及式（I）的6-氨基（氮杂）二氢化茚化合物，其中Ar是苯基或芳族5-或6-元C-结合的杂芳族基团，其中Ar可以携带1个基团R6，并且其中Ar也可以携带I或2个基团Rb; X为N或CH; E为CR6R7或NR3; R 1是C 1 -C 4烷基，C 3 -C 4环烷基，C 3 -C 4环烷基甲基，C 3 -C 4链烯基，氟化C 1 -C 4烷基，氟化C 3 -C 4环烷基，氟化C 3 -C 4环烷基甲基， C4-烯基，甲酰基或C1-C3-烷基羰基; R1a是H或R1a，R2或R1a和R2a同时为（CH2）n，n为1,2,3或4; R2和R2a各自独立地为H，CH3，CH2F，CHF2或CF3; R3是H或C，-C4-烷基; 和这些化合物的生理上耐受的酸加成盐。本发明还涉及包含至少一种式（I）化合物或其药学上可接受的盐的药物组合物和治疗易受多巴胺D3受体配体治疗的医学疾病的方法，所述方法包括施用有效量的至少一种式（I）化合物或其药学上可接受的盐。

68. 发明申请

US20080096934A1 Aminoethylaromatic Compounds Suitable For Treating Disorders That Respond To Modulation Of The Dopamine D3 Receptor 失效
公开(公告)号：US20080096934A1
公开(公告)日：2008-04-24
申请号：US11665288
申请日：2005-10-14
申请人： Karla Drescher , Andreas Haupt , Liliane Unger , Sean Turner , Wilfried Braje , Roland Grandel
发明人： Karla Drescher , Andreas Haupt , Liliane Unger , Sean Turner , Wilfried Braje , Roland Grandel
IPC分类号： A61K31/4439 , A61K31/18 , A61K31/40 , C07C311/00 , C07D213/76 , C07D401/06 , C07D207/09 , A61P25/00 , A61K31/44
CPC分类号： C07D213/76 , C07C311/21 , C07C311/29 , C07C2601/02 , C07D207/09
摘要： The present invention relates to aromatic compounds of the formula I wherein Ar is phenyl or an aromatic 5- or 6-membered C-bound heteroaromatic radical, wherein Ar may carry 1 radical Ra and wherein Ar may also carry 1 or 2 radicals Rb; X is N or CH; E is CR6R7 or NR3; R1 is C1-C4-alkyl, C3-C4-cycloalkyl, C3-C4-cycloalkylmethyl, C3-C4-alkenyl, fluorinated C1-C4-alkyl, fluorinated C3-C4-cycloalkyl, fluorinated C3-C4-cycloalkylmethyl, fluorinated C3-C4-alkenyl, formyl or C1-C3-alkylcarbonyl; R1a is H, C1-C4-alkyl, C3-C4-cycloalkyl, C3-C4-cycloalkylmethyl, C3-C4-alkenyl, fluorinated C1-C4-alkyl, fluorinated C3-C4-cycloalkyl, fluorinated C3-C4-cycloalkylmethyl, fluorinated C3-C4-alkenyl, or R1a and R2 together are (CH2)n with n being 2, 3 or 4, or R1a and R2a together are (CH2)n with n being 2, 3 or 4; R2 and R2a are are independently of each other H, C1-C4-alkyl or fluorinated C1-C4-alkyl or R2a and R2 together are (CH2)m with m being 1, 2, 3, 4 or 5; R3 is H or C1-C4-alkyl; R6, R7 independently of each other are selected from H, fluorine, C1-C4-alkyl and fluorinated C1-C4-alkyl or together form a moiety (CH2)p with p being 2, 3, 4 or 5; and the physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.

69. 发明申请

US20080045493A1 Heterocyclic Compounds Suitable For Treating Disorders That Respond To Modulation Of The Dopamine D3 Receptor 有权
公开(公告)号：US20080045493A1
公开(公告)日：2008-02-21
申请号：US11665399
申请日：2005-10-14
申请人： Karla Drescher , Andreas Haupt , Liliane Unger , Sean Turner , Wilfried Braje , Roland Grandel , Christophe Henry , Gisela Backfisch , Armin Beyerbach , Wilfried Lubisch
发明人： Karla Drescher , Andreas Haupt , Liliane Unger , Sean Turner , Wilfried Braje , Roland Grandel , Christophe Henry , Gisela Backfisch , Armin Beyerbach , Wilfried Lubisch
IPC分类号： A61K31/397 , A61K31/4025 , A61K31/4192 , A61K31/4196 , A61K31/422 , A61K31/423 , A61K31/4245 , A61K31/427 , A61K31/428 , A61K31/433 , A61K31/445 , A61K31/4523 , A61K31/496 , A61K31/4965 , A61K31/501 , A61K31/502 , A61K31/506 , A61K31/517 , A61K31/5375 , A61K31/538 , A61K31/541 , A61P25/16 , C07D205/04 , C07D207/08 , C07D211/28 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D405/12 , C07D409/12 , C07D411/12 , C07D413/10 , C07D413/12 , C07D413/14 , C07D417/12
CPC分类号： C07D413/14 , C07D205/04 , C07D207/09 , C07D211/28 , C07D401/04 , C07D401/12 , C07D403/04 , C07D405/12 , C07D409/12 , C07D413/10 , C07D413/12
摘要： The invention relates to compounds of the formula (I) wherein n is 0, 1 or 2; G is CH2 or CHR3; R1 is H, C1-C6-alkyl, C1-C6-alkyl substituted by C3-C6-cycloalkyl, C1-C6-hydroxyalkyl, fluorinated C1-C6-alkyl, C3-C6-cycloalkyl, fluorinated C3-C6-cycloalkyl, C3-C6-alkenyl, fluorinated C3-C6-alkenyl, formyl, acetyl or propionyl; R2, R3 and R4 are, independently of each other, H, methyl, fluoromethyl, difluoromethyl, or trifluoromethyl; A is phenylene, pyridylene, pyrimidylene, pyrazinylene, pyridazinylene or thiophenylene, which can be substituted by one or more substituents selected from halogen, methyl, methoxy and CF3; E is NR5 or CH2, wherein R5 is H or C1-C3-alkyl; Ar is a cyclic radical selected from the group consisting of phenyl, a 5- or 6-membered heteroaromatic radical comprising as ring members 1, 2 or 3 heteroatoms selected from N, O and S and a phenyl ring fused to a saturated or unsaturated 5- or 6-membered carbocyclic or heterocyclic ring, where the heterocyclic ring comprises as ring members 1, 2 or 3 heteroatoms selected from N, O and S and/or 1, 2 or 3 heteroatom-containing groups each independently selected from NR8, where R8 is H, C1-C4-alkyl, fluorinated C1-C4-alkyl, C1-C4-alkylcarbonyl or fluorinated C1-C4-alkylcarbonyl, and where the cyclic radical Ar may carry 1, 2 or 3 substituents Ra, wherein the variable Ra has the meanings given in the claims and in the description; and physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.

70. 发明授权

US07026311B2 Dibenzodiazepine derivatives, their preparation and use 失效
标题翻译：二苯并二氮杂衍生物，其制备和用途
公开(公告)号：US07026311B2
公开(公告)日：2006-04-11
申请号：US10041556
申请日：2002-01-10
申请人： Wilfried Lubisch , Roland Grandel , Wilfried Braje , Thomas Subkowski , Reinhold Mueller , Wolfgang Wernet , Karla Drescher
发明人： Wilfried Lubisch , Roland Grandel , Wilfried Braje , Thomas Subkowski , Reinhold Mueller , Wolfgang Wernet , Karla Drescher
IPC分类号： A61K31/55 , A61P9/00 , C07D487/06
CPC分类号： C07D487/06
摘要： The invention relates to compounds of the formula I and their tautomeric forms, possible enantiomeric and diastereomeric forms and their prodrugs, and to their preparation and use, where A, B, R1 and X1 have the meanings given in the description.
摘要翻译：本发明涉及式I化合物及其互变异构形式，可能的对映体和非对映体形式及其前药，以及其制备和用途，其中A，B，R 1和X 1 具有说明书中给出的含义。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式